A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

Phase 1

Recruiting

• Conditions: Parkinson Disease
• Interventions: Drug: LY4006896; Drug: Placebo

• Registration Number: NCT06809400
• Lead Sponsor: Eli Lilly and Company

Brief Summary

The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.

Detailed Description

The screening period will be up to 120 days for participants with Parkinson's disease who receive 4 doses, and up to 35 days for healthy participants who receive 1 dose. The treatment and follow-up duration will be up to 61 weeks for participants with Parkinson's disease, and 48 weeks for healthy participants. The total study duration will be up to 78 weeks for participants with Parkinson's disease, and 53 weeks for healthy participants.

Study Timeline

• Study First Submitted: 2025-01-31
• Study First Submitted QC: 2025-02-04
• Study First Posted: 2025-02-05
• Study Start: 2025-02-18
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-16
• Last Update Posted: 2025-04-17
• Primary Completion: 2027-11
• Study Completion: 2027-11

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 127

Inclusion Criteria

Part A Single Ascending Dose (SAD) and B Multiple Ascending Dose (MAD)

• Have a body mass index within the range of 18 to 34 kilogram/square meter (kg/m²) (inclusive).
• For Japanese participants: To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan.
• Have venous access sufficient to allow for blood sampling or administration of study intervention for IV administration, or both.

Part A (SAD) Only

• Are overtly healthy
• For Chinese participants: To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be exclusive Chinese descent and born in China.

Part B (MAD) Only

• Diagnosis of Parkinson's disease per United Kingdom (UK) Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria.
• If presently untreated for Parkinson's disease, clinical status is not expected to require changes in symptomatic treatment within 52 weeks from baseline.
• If presently being treated for Parkinson's disease, receiving a stable dose of symptomatic dopaminergic therapy, including monoamine oxidase-B inhibitor, levodopa/carbidopa or dopamine agonist for at least 90 days prior to baseline and not expected to change within 52 weeks.
• Have a Montreal Cognitive Assessment (MoCA) score of greater than or equal to (≥) 26.

Exclusion Criteria

Part A (SAD) and B (MAD)

• Have significant neurological disease affecting the central nervous system (CNS) (other than Parkinson's disease in Part B cohorts) that may affect the participant's ability to complete the study.
• Have a history or presence of serious or unstable illnesses or conditions that, in the investigator's opinion, could interfere with the analyses in this study, or increase risk for study intervention administration, or result in a participant's life expectancy of less than 24 months.
• Have known allergies to LY4006896, related compounds, or any components of the formulation, or history of allergic reactions to any transferrin receptor antibodies.
• Have significant allergies to humanize monoclonal antibodies.
• Have clinically significant multiple or severe drug allergies (including, but not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis); or intolerance to topical corticosteroids, or severe posttreatment hypersensitivity reactions.
• Have history or presence of uncontrolled asthma, significant autoimmune disease, hereditary angioedema, or known history of common variable immune deficiency.
• Evidence of clinically significant anemia.

Part A (SAD) Only

• Have an abnormal blood pressure or pulse rate, or both, as determined by the investigator, or a preexisting history of hypertension.

Part B (MAD) Only

• Have an abnormal blood pressure or pulse rate, or both, as determined by the investigator, or have uncontrolled hypertension, defined as a systolic blood pressure >150 mm Hg or a diastolic blood pressure >95 mm Hg at Screening or Treatment Visits.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Part A LY4006896 + Placebo	LY4006896	Healthy participants will receive a single escalating dose of LY4006896 and matching placebo.
Part B LY4006896 + Placebo	Placebo	Participants with Parkinson's disease will receive multiple escalating doses of LY4006896 and matching placebo.

Primary Outcome Measures

Name	Time	Method
Number of Participants with TEAEs Part B	Baseline to Week 61
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Part A	Baseline to Week 48
Number of Participants with Treatment-Emergent Adverse Events (TEAEs) Part A	Baseline to Week 48
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Part B	Baseline to Week 61

Secondary Outcome Measures

Name	Time	Method
PK: AUC of LY4006896 ARC-Associated Antisense Part B	Baseline to Week 61
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4006896 Part A	Baseline to Week 48
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4006896 Part B	Baseline to Week 61
PK: Area Under the Concentration versus Time Curve (AUC) of LY4006896 Antibody-Small Interfering RNA (siRNA) Conjugate (ARC)-associated antisense Part A	Baseline to Week 48

Trial Locations

Locations (2)

Collaborative Neuroscience Network - CNS; 🇺🇸 Los Alamitos, California, United States

PPD Development, LP; 🇺🇸 Austin, Texas, United States